Raghav Chandra / Chief Financial Officer
Perspectives from a life in leadership.
The latest essay
Indian generics companies often present USFDA remediation spending as a one-off that investors can add back. That presentation teaches boards to under-fund the laboratory that decides whether a plant may sell at all.
Read the essayIndian generics companies often present USFDA remediation spending as a one-off that investors can add back. That presentation teaches boards to under-fund the laboratory that decides whether a plant may sell at all.
In Indian branded generics, revenue is recognised when stock reaches a stockist, not when a patient buys it. A board that sees only primary sales is judging the push, not the business.
Indian generics companies still advertise how many ANDAs they have filed and had approved. The count measures effort. Value depends on how many competitors each product will meet, what price survives them and whether the named plant can supply.